Apic Bio
Apic Bio, Inc. is a gene therapy company focused on developing treatments for rare and undertreated neurological and liver diseases. Established in 2017 and headquartered in Cambridge, Massachusetts, the company is advancing several gene therapies, particularly targeting Alpha-1 Antitrypsin Deficiency, genetic Amyotrophic Lateral Sclerosis, and other central nervous system disorders. Apic Bio's innovative approach employs a gene therapy platform that utilizes a dual-function vector to silence defective genes while augmenting the production of healthy proteins. This technology aims to provide effective treatment options for patients suffering from genetic conditions, addressing significant unmet medical needs in the healthcare landscape.
MabPlex International Ltd is a contract development and manufacturing organization specializing in biopharmaceuticals, including monoclonal antibodies, recombinant proteins, antibody-drug conjugates, and bispecifics. Founded in 2013 and headquartered in Yantai, China, with an additional office in Fremont, California, MabPlex provides a range of services from drug development to manufacturing. The company offers customized mammalian cell media, cell banking, and active pharmaceutical ingredient manufacturing, as well as biologics and ADC fill and finish services. MabPlex aims to deliver high-quality solutions for biomanufacturing, catering to partners globally.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.